Servier Canada
Oncaspar®
ONCASPAR logo; ONCASPAR pegaspargase injection.

Patient Profiles

Meet Charlotte‡ — a patient with ALL

63 years of age1

Initial presentation5

  • Charlotte was referred to her oncologist with symptoms including fatigue, night sweats, dizziness, and easy bruising

Diagnosis1,5

  • Bone marrow aspiration and biopsy confirmed ALL

Treatment plan1

  • Charlotte started ONCASPAR® as part of a multi-agent chemotherapy regimen
  • To decrease the risk and severity of hypersensitivity and infusion reactions, Charlotte’s oncologist included steroids as part of her premedication

To assess for silent inactivation due to premedication, Charlotte’s doctor proactively initiated therapeutic drug monitoring to regularly assess trough serum L-asparaginase activity1

Photograph of Charlotte, a 63-year-old woman.

Consider ONCASPAR® as part of the chemotherapy regimen for your patients like Charlotte

aBFM: augmented Berlin-Frankfurt-Münster; ALL: acute lymphoblastic leukemia; BSA: body surface area; CNS: central nervous system; CSF: cerebrospinal fluid; DFCI: Dana-Farber Cancer Institute; ELISA: enzyme-linked immunosorbent assay; IM: intramuscular; IV: intravenous; PD: pharmacodynamics; PK: pharmacokinetics; NCCN: National Comprehensive Cancer Network®; TDM: therapeutic drug monitoring.

* Clinical significance has not been established.

† Comparative clinical significance has not been established.

‡ Fictitious cases. May not be representative of all patients.

§ Native E. coli L-asparaginase is not available in Canada.

References: 

  1. ONCASPAR® Product Monograph. Servier Canada. August 20, 2024.
  2. ONCASPAR_CPID Redacted.
  3. ASPARLAS® Product Monograph. Servier Canada. March 8, 2024.
  4. RYLAZE™ Product Monograph. Jazz Pharmaceuticals Canada Inc.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed November 8, 2024.
  6. Vrooman LM et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.
Back to top

Stay Connected with Servier Canada

Stay up to date on disease information, treatment options, our products, and patient support programs.

Sign Up